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OBJECTIVE — Sleep restriction results in decreased insulin sensitivity and glucose tolerance
in healthy subjects. We hypothesized that sleep duration is also a determinant of insulin sensi-
tivity in patients with type 1 diabetes.
RESEARCH DESIGN AND METHODS — We studied seven patients (three men, four
women) with type 1 diabetes: mean age 44  7 years, BMI 23.5  0.9 kg/m
2, and A1C 7.6 
0.3%.Theywerestudiedonceafteranightofnormalsleepdurationandonceafteranightofonly
4 h of sleep. Sleep characteristics were assessed by polysomnography. Insulin sensitivity was
measured by hyperinsulinemic euglycemic clamp studies with an infusion of [6,6-
2H2]glucose.
RESULTS — Sleep duration was shorter in the night with sleep restriction than in the unre-
strictednight(4698.5vs.2227.1min,P0.02).Sleeprestrictiondidnotaffectbasallevels
of glucose, nonesteriﬁed fatty acids (NEFAs), or endogenous glucose production. Endogenous
glucoseproductionduringthehyperinsulinemicclampwasnotalteredduringthenightofsleep
restriction compared with the night of unrestricted sleep (6.2 0.8 vs. 6.9 0.6 mol   kg lean
body mass
1   min
1, NS). In contrast, sleep restriction decreased the glucose disposal rate
during the clamp (25.5  2.6 vs. 22.0  2.1 mol   kg lean body mass
1   min
1, P  0.04),
reﬂecting decreased peripheral insulin sensitivity. Accordingly, sleep restriction decreased the
rate of glucose infusion by 21% (P  0.04). Sleep restriction did not alter plasma NEFA levels
during the clamp (143  29 vs. 133  29 mol/l, NS).
CONCLUSIONS — Partialsleepdeprivationduringasinglenightinducesperipheralinsulin
resistanceinthesesevenpatientswithtype1diabetes.Therefore,sleepdurationisadeterminant
of insulin sensitivity in patients with type 1 diabetes.
Diabetes Care 33:1573–1577, 2010
I
ntensive insulin therapy is essential for
optimal glucoregulation in type 1 dia-
betes because the degree and duration
of hyperglycemia determine the inci-
dence of complications (1). However,
glucoregulation cannot be normalized in
patients with type 1 diabetes, as reﬂected
by relatively large intra-individual varia-
tionsofbloodglucoselevels.Subtleintra-
individual variations in glucoregulation
and insulin sensitivity in these patients
depend on variations in physiological de-
terminants such as dietary factors and
exercise (2,3). In contrast to healthy sub-
jects, however, patients with type 1 dia-
betes are unable to compensate for these
physiological variations, other than by
adaptations of the dose of exogenous
insulin.
Normal glucose homeostasis shows a
diurnal pattern with variations in glucose
tolerance, in which sleep characteristics
play a key role (4). In this respect, sleep
duration may be particularly relevant be-
cause sleep curtailment is a common as-
pect of our modern 24-h society (5,6). A
reduction in sleep duration impairs glu-
cosetoleranceinhealthysubjects(7).The
effects of reduction of sleep duration on
insulin sensitivity have not been studied
in patients with type 1 diabetes.
Wehypothesizedthatpartialsleepre-
striction decreases insulin sensitivity in
patients with type 1 diabetes, which may
contribute to intra-individual variations
in glucoregulation. Therefore, we com-
pared the effects of a single night of re-
ducedsleepdurationwiththoseofanight
of normal sleep duration on hepatic and
peripheral insulin sensitivity, as assessed
by hyperinsulinemic euglycemic clamp
studies combined with tracer dilution of
[6,6-
2H2]glucose in patients with type 1
diabetes.
RESEARCH DESIGN AND
METHODS— We included nine pa-
tients (ﬁve men and four women) with
type 1 diabetes on stable continuous sub-
cutaneous insulin pump therapy. Diag-
nostic criteria for type 1 diabetes were
pastorpresentpositiveantibodiesagainst
GAD or islet cells and plasma free C-
peptide levels 0.3 nmol/l. All partici-
pants were screened at our outpatient
clinicpriortothestudy.Theirweighthad
been stable for at least 3 months prior to
participationinthisstudy.A1Clevelshad
been below 8.5% during the year prior to
the start of the study. Exclusion criteria
were a BMI 26 kg/m
2, clinical signs of
autonomic neuropathy, known sleep dis-
orders, habitual sleep duration of less
t h a n6ho rmore than 9 h, psychiatric
disorders, and use of sleep medication,
-blocking agents, or prokinetic drugs.
All patients had normal blood pressure
and serum creatinine levels and urinary
microalbumin excretion rates below 30
mg/24 h.
The study was approved by the med-
ical ethical committee of the Leiden Uni-
versity Medical Center, and written
informed consent was obtained from all
subjects prior to the study.
The subjects were studied on 3 days,
separated by intervals of at least 3 weeks.
Subjects kept a detailed diary of their diet
and physical activity for 3 days prior to
each study day and were asked to main-
tain a standardized schedule of bedtimes
and mealtimes in accordance with their
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AW7; Cambridge Neurotechnology,
Cambridge, U.K.) was performed to ob-
jectively assess patterns of habitual active
and inactive (sleep) periods for 7 days
prior to the actual study, including one
weekend. In addition, self-reported sleep
duration and sleep quality were assessed
using validated questionnaires (Pitts-
burgh Sleep Quality Index, Epworth
Sleepiness scale, and Berlin Question-
naire) (8–10).
Subjectswereadmittedtoourclinical
research center the night preceding each
study day and spent 8.5 h in bed from
2300 h to 0730 h on all three occasions.
Subjects fasted throughout these nights
from 2200 h onwards. The ﬁrst study day
served to let subjects become accustomed
to sleep conditions in a research setting.
The optimal overnight infusion rate of in-
sulin was determined in each subject
prior to the start of the study. Subse-
quently, this same individualized infu-
sion rate was used in both sleeping
experiments. Subjects were instructed
not to alter lifestyle habits during the
study period. Premenopausal women
were studied in the follicular phase of
their menstrual cycle.
Subjects were randomly assigned to
partialsleepdeprivationoneitherthesec-
ond (n  4) or third (n  5) study occa-
sion.Duringthenightofsleeprestriction,
subjects also spent 8.5 h in bed but were
only allowed to sleep from 0100 h to
0500 h. They were allowed to read or
watch movies in an upward position, and
their wakefulness was monitored and as-
sured if necessary.
Polysomnography
Sleep was visually scored for each of the
threenightsaccordingtotheguidelinesof
the American Association of Sleep Medi-
cine (AASM) (11). In short, scoring of
sleep stages depends on electroencepha-
lography,eyemovements,andsubmental
muscle activity. To detect possible sleep
disorders that might affect the study, re-
spiratory movements were recorded by
measurement of changes in nasal pres-
sures and of truncal respiratory move-
ments. Recordings were made using
a portable polysomnography (PSG)
recorder (Titanium; Embla Systems,
Broomﬁeld, CO). Sleep and wake stages
were visually scored in consecutive ep-
ochs of 30 s, resulting in a list of epochs
spent in wake, stages I (drowsiness), II,
III, and rapid eye movement (REM)
dream sleep. The times at which subjects
went to bed and turned out the lights as
well as times of getting out of bed were
noted. The lists of stages were used to cal-
culate the duration of time spent each
night in the above-mentioned sleep and
wake stages. These durations were also
expressedaspercentagesoftotalsleepdu-
ration,deﬁnedasthesummeddurationof
sleep stages I, II, III, and REM.
Hyperinsulinemic euglycemic clamp
studies
Hyperinsulinemic euglycemic clamp stud-
ies were performed the day after the sec-
ond and third study occasions. After an
overnightfast,acatheterwasinsertedinto
an antecubital vein for infusion of iso-
topes, glucose, and insulin, and a sam-
pling catheter was inserted into a dorsal
handveinofthecontralateralarm.Forall
blood samples, the heated hand tech-
nique was used to obtain arterialized
blood (12). A primed (17.6 mol/kg
1)
continuous (0.22 mol   kg
1   min
1)
infusion of [6,6-
2H2]glucose (Cambridge
Isotope Laboratory, Andover, MA) was
started at 0830 h, after basal blood sam-
ples had been taken for determination of
background glucose enrichment. Labeled
glucose was infused by a Pilot C syringe
pump (Fresenius Vial, Brezins, France).
Blood samples were obtained after 160,
170, and 180 min of [6,6-
2H2]glucose in-
fusion for assessment of glucose kinetics
in the basal state and concentrations of
glucoseandplasmanonesteriﬁedfattyac-
ids (NEFAs).
Subsequently, administration of sub-
cutaneous insulin was stopped and infu-
sion of intravenous insulin was started,
using the method of DeFronzo et al. (13).
Brieﬂy, this consisted of a primed (80
mU   m
2   min
1 for 5 min and subse-
quently 40 mU   m
2   min
1 for 5 min),
followed by continuous (20 mU   m
2  
min
1) infusion of insulin (Actrapid,
Novo Nordisk, Alphen a/day Rijn, the
Netherlands), dissolved in sterile NaCl
0.9%, using a Pilot C syringe pump. A
variableinfusionofglucose20%enriched
with 3% [6,6-
2H2]glucose was started 4
min after the start of insulin infusion.
Plasma glucose concentrations were mea-
sured in intervals of 5 min with a bedside
calibrated glucose analyzer (Accu-Chek;
Roche,Mannheim,Germany),andthein-
fusionrateofglucose20%wasadjustedin
order to keep the plasma glucose levels
constant at 5.0 mmol/l during the clamp
study. Blood samples were obtained after
150, 160, 170, and 180 min of combined
insulin and [6,6-
2H2]glucose infusion for
assessmentofglucosekineticsandofcon-
centrations of glucose, insulin, and
plasma NEFA.
Biochemical analysis
Serum concentrations of glucose were
measured using a fully automated Modu-
lar P 800 analyzer (Roche/Hitachi; Mann-
heim, Germany) with intra-assay
variations of 1%. Serum insulin concen-
trations were measured by enzyme la-
beled chemiluminescent immunometric
assay(Immulite2500;Siemens,BadNau-
heim, Germany) with an intra-assay coef-
ﬁcient of variation (CV) of 4%. NEFA
levels were determined spectrophoto-
metrically by enzymatic colorimetric
acyl-CoA synthase/acyl-CoA oxidase as-
say(WAKOChemicals,Neuss,Germany)
with intra-assay CV of 2.7%. Enrichment
of plasma [6,6-
2H2]glucose was deter-
mined in a single analytical run, using gas
chromatography coupled to mass spec-
trometry, as described previously (14).
All isotope enrichments were measured
on a gas chromatograph mass spectrome-
ter (model 6890/5973; Hewlett-Packard,
Palo Alto, CA).
Calculations
Isotopic steady state was achieved during
the ﬁnal 30 min of the basal period and
the ﬁnal 30 min of the hyperinsulinemic
clamp study. Therefore, the rates of ap-
pearance (Ra) and disappearance (Rd)o f
glucose were calculated as the tracer infu-
sion rates divided by the tracer-to-tracee
ratios. Endogenous glucose production
(EGP) during the basal steady state is
equal to Ra of glucose, whereas EGP dur-
ing the hyperinsulinemic clamp study
was calculated as the difference between
Ra and the glucose infusion rates.
Statistical analysis
Data are presented as mean  SEM. Dif-
ferencesbetweentheeffectsofthenightof
normal sleep duration and the night of
partial sleep restriction were analyzed by
the Wilcoxon signed rank test for paired
samples. All analyses were performed us-
ing SPSS for Windows, version 16.0
(SPSS, Chicago, IL). Signiﬁcance was ac-
cepted at P  0.05.
RESULTS
Clinical characteristics
The results of two of the nine patients
were excluded because of nocturnal hy-
poglycemia and subsequent nocturnal
hyperglycemia during the study (n  1),
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ously undetected sleep apnea syndrome
(n  1). Therefore, the analyses included
the data of seven patients (three men) for
analysis. Mean age of these seven subjects
was 44.3  6.6 years, mean weight
72.0  4.0 kg, mean height 175  3 cm,
and mean BMI 23.5  0.9 kg/m
2. Mean
A1C of the patients was 7.6  0.3%, and
mean duration of diabetes was 23  3.5
years. All subjects had normal results on
validated sleep questionnaires. Self-
reported sleep duration and recorded ha-
bitual sleep duration by actigraphy were
not different (475  8 vs. 490  7 min,
P  0.12).
Effects of partial sleep restriction on
polysomnographic parameters
Sleep duration was considerably shorter
in the night with partial sleep restriction,
compared with the night with normal
sleepduration(P0.02)(Table1).Sleep
in the sleep-deprived night showed a
higher proportion of stage III sleep (P 
0.02) and a lower proportion of REM
sleep (P  0.04). The proportions of time
spent in other stages did not differ be-
tween the conditions.
Effects of partial sleep restriction on
basal metabolic parameters
The mean overnight rate of subcutaneous
infusion of insulin was 0.7 IE/h and was
identical in both conditions (Table 1).
Compared with normal sleep duration,
partial sleep deprivation did not alter
basal levels of glucose or NEFA measured
the following morning. In addition, par-
tial sleep restriction did not affect basal
EGP assessed by primed, continuous in-
fusion of [6,6-
2H2]glucose.
Effects of partial sleep restriction on
metabolic parameters during
hyperinsulinemic euglycemic clamp
conditions
Steadystateglucoseandinsulinlevelsdid
not differ between the two clamp studies
(Table 1 and Fig. 1). Sleep restriction did
not affect EGP during the clamp condi-
tions. However, sleep restriction de-
creased the rate of glucose disposal (Rd)
during the clamp by 14% (P  0.04).
Accordingly, the rate of infusion of glu-
cose necessary to maintain constant
plasma glucose levels during the hyperin-
sulinemic clamp study was 21% lower
after the night of reduced sleep duration
than after the night of normal sleep dura-
tion (P  0.04), reﬂecting decreased pe-
ripheral insulin sensitivity. There was no
signiﬁcant effect of partial sleep restric-
tion on plasma NEFA levels.
CONCLUSIONS— In this study, we
assessed the effects of a single night of
partial sleep restriction on insulin sensi-
tivityinpatientswithtype1diabetes.The
results indicate that a single night of par-
tial sleep restriction reduces insulin sen-
sitivity of insulin-stimulated glucose
uptake by 14–21%. Partial sleep restric-
tion did not signiﬁcantly affect basal glu-
cose metabolism. We conclude that sleep
duration is a determinant of peripheral
insulin sensitivity in patients with type 1
diabetes.
Inthecurrentstudyweincludedthe
data of only seven patients with type 1
diabetes. The strictly controlled design
ofthispathophysiologicalstudyincom-
bination with the fact that each subject
served as his/her own control enabled
us to establish subtle effects of partial
sleep deprivation on parameters of in-
sulin sensitivity. Nonetheless, larger
numbers of subjects are required to as-
sess the involvement of relevant patient
characteristics such as sex, age, and an-
tecedent glucoregulation on the effects
of sleep restriction on insulin sensi-
tivity.
This is the ﬁrst study that documents
an adverse effect of partial sleep restric-
tion on insulin sensitivity in patients with
type 1 diabetes. In healthy subjects, sleep
restriction induces insulin resistance and
reducesglucosetolerance(7,15).Byanal-
ogy, it can be expected that sleep restric-
tion increases postprandial glucose levels
in patients with type 1 diabetes in the ab-
sence of concurrent adaptations of the
dose of exogenous insulin.
Insulinsensitivityisnotstaticbutvar-
ies over time within individuals. This is
also reﬂected by the current study in
patients with type 1 diabetes. Several ep-
idemiological studies documented an as-
sociation between chronic partial sleep
restrictionanddevelopmentofinsulinre-
sistance and type 2 diabetes (5,16,17).
Therefore, exposure to chronic sleep re-
strictionmightcontributetoinsulinresis-
tance in patients with type 1 diabetes. In
turn, insulin resistance is associated with
an increased risk for microvascular and
macrovascularcomplicationsintype1di-
abetes (18).
Unfortunately, the current study was
notdesignedtoelucidatethemechanisms
involved in the induction of insulin resis-
tance by partial sleep deprivation. A sin-
gle night of partial sleep restriction to
4.5 h does not cause endocrine changes
that simply explain the induction of insu-
lin resistance (19). Subsequent nights of
partial sleep deprivation induce subtle
changes in cortisol and catecholamine se-
cretion (7,15,20). However, the relations
Table 1—The effects of a night of normal sleep duration versus a night of sleep duration
restricted to4ho nsleep parameters assessed by PSG, basal and insulin-stimulated glucose,
and fatty acid metabolism in seven patients with type 1 diabetes
Normal sleep
Partial sleep
deprivation P
Sleep parameters
TST (min) 469  8.5 222  7.1 0.02
Stage 1 (% of TST) 10.6  1.0 10.2  2.1 0.49
Stage 2 (% of TST) 44.4  2.8 40.4  2.4 0.13
Stage 3 (% of TST) 22.7  3.4 35.3  4.4 0.02
REM sleep (% of TST) 22.2  1.7 13.7  2.3 0.04
Wake time during sleep (% of total sleep period) 4.2  0.7 5.4  2.3 0.87
Basal values
Glucose (mmol/l) 7.2  1.0 6.7  1.4 0.87
NEFA (mol/l) 673  125 591  99 0.35
EGP (mol   kg LBM
1   min
1) 17.6  0.9 16.3  1.0 0.31
Hyperinsulinemic euglycemic clamp study
Glucose (mmol/l) 5.1  0.2 5.2  0.1 0.23
Insulin (mU/l) 24.0  2.2 24.9  1.5 0.40
NEFA (mol/l) 143  29 133  29 0.69
EGP (mol   kg LBM
1   min
1) 6.2  0.8 6.9  0.6 0.74
Glucose Rd (mol   kg LBM
1   min
1) 25.5  2.6 22.0  2.1 0.04
Glucose infusion rate (mol   kg LBM
1   min
1) 19.0  2.9 14.9  2.1 0.04
Data are means  SEM. Data in bold represent statistical signiﬁcance. LBM, lean body mass; TST, total sleep
time.
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on endocrine homeostasis and glucose
tolerance are uncertain. Partial sleep de-
privation for a single and subsequent
nights increased the sympathetic tone
based on recordings of heart rate variabil-
ity after sleep deprivation (21,22). How-
ever, the relationship between elevated
sympathovagal balance at the level of the
heart and the sympathetic outﬂow to
liver, muscles, and adipose tissue is un-
certain (21).
Interestingly, in addition to sleep du-
ration, the composition of sleep in terms
of sleep stages is also a determinant of
insulin sensitivity. Selective suppression
of slow-wave sleep, without a change in
total sleep duration, decreased glucose
tolerance in healthy subjects (23). The
differentialeffectsofalteredsleepcompo-
sition versus decreased total sleep dura-
tion on insulin sensitivity awaits further
study.
Data on sleep physiology and sleep
disturbances in patients with type 1 dia-
betes are rare. Jauch-Chara et al. (24)
reported alterations in neuroendocrine
sleep architecture and a trend toward less
slow-wavesleepin14patientswithtype1
diabetes. Children with type 1 diabetes
have a more disrupted sleep than healthy
children (25). If type 1 diabetes indeed
causes disruption of sleep patterns, this
may in turn impair glucose regulation,
creating a vicious circle.
In conclusion, the present study indi-
cates that partial sleep restriction de-
creases insulin sensitivity of insulin-
mediated glucose uptake in patients with
type 1 diabetes. It is important to further
assess the relationship between sleep
physiology and glucoregulation in pa-
tientswithtype1diabetes.Sleepduration
might become another therapeutic target
to improve glucoregulation in type 1
diabetes.
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